Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-10-20
|
LEE011 (ribociclib) |
advanced breast cancer |
3b |
Novartis (Switzerland) |
Cancer - Oncology |
2016-10-20
|
sofosbuvir, velpatasvir (GS-5816) and voxilaprevir (GS-9857) |
genotype 1-6 chronic hepatitis C virus (HCV) infection |
3 |
Gilead Sciences (USA - CA) |
Infectious diseases |
2016-10-20
|
Xgeva® (denosumab) |
skeletal-related event (SRE) in patients with multiple myeloma |
3 |
Amgen (USA - CA) Daiichi Sankyo (Japan) |
Cancer - Oncology - Bone diseases |
2016-10-20
|
Xgeva® (denosumab) |
skeletal-related event (SRE) in patients with multiple myeloma |
3 |
Amgen (USA - CA) Daiichi Sankyo (Japan) |
Cancer - Oncology - Bone diseases |
2016-10-19
|
ganaxolone i |
status epilepticus |
1 |
Marinus Pharmaceuticals (USA - PA) |
Rare diseases - CNS diseases - Neurological diseases |
2016-10-19
|
remimazolam |
procedural sedation in patients undergoing colonoscopy |
3 |
Paion (Germany) |
CNS diseases |
2016-10-19
|
small molecule immune checkpoint antagonist targeting programmed death ligand-1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA) |
|
|
Curis (USA - MA) |
Cancer - Oncology |
2016-10-19
|
small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) |
|
|
Curis (USA - MA) |
Cancer - Oncology |
2016-10-18
|
GED-0301 (mongersen) |
Crohn disease |
1 |
Celgene (USA - NJ) |
Autoimmune diseases - Inflammatory diseases - Digestive diseases |
2016-10-18
|
tirasemtiv |
amyotrophic lateral sclerosis (ALS) |
3 |
Cytokinetics (USA - CA) |
Neurodegenerative diseases - Rare diseases |
2016-10-16
|
lorlatinib (PF-06463922) |
ALK-positive non small cell lung cancer (NSCLC) and ROS1-positive NSCLC |
2 |
Pfizer (USA - NY) |
Cancer - Oncology |
2016-10-16
|
Raxone® |
Duchenne muscular dystrophy (DMD) |
3 |
Santhera Pharmaceuticals (Switzerland) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
2016-10-15
|
abicipar pegol (anti-VEGF DARPin - AGN-150998/MP0112) |
diabetic macular edema |
2 |
Molecular Partners (Switzerland) Allergan (Ireland) |
Ophtalmological diseases - Metabolic diseases |
2016-10-13
|
ublituximab and ibrutinib |
chronic lymphocytic leukemia |
3 |
TG Therapeutics (USA - NY) |
Cancer - Oncology |
2016-10-13
|
custirsen |
non-small cell lung cancer (NSCLC) |
3 |
OncoGenex Pharmaceuticals (USA - WA) |
Cancer - Oncology |
2016-10-13
|
CicloMulsion® (Cremophor®-free intravenous cyclosporine formulation) |
acute kidney injury |
2 |
NeuroVive Pharmaceutical (Sweden) |
Kidney diseases - Renal diseases |
2016-10-12
|
PBI-4050 - 3-pentylbenzenacetic acid sodium salt |
Alström syndrome |
2 |
ProMetic Life Sciences (Canada) |
Rare diseases - Genetic diseases |
2016-10-12
|
ADC-1013/JNJ-64457107 |
advanced stage solid tumors |
1 |
Janssen Research & Development, a J&J company (USA - NJ) Alligator Bioscience (Sweden) |
Cancer - Oncology |
2016-10-11
|
Onivyde™ (MM-398 - nanoliposomal irinotecan injection) |
metastatic pancreatic cancer |
3 |
Merrimack Pharmaceuticals (USA - MA) |
Cancer - Oncology |
2016-10-11
|
quizartinib (AC220) |
acute myeloid leukemia |
3 |
Daiichi Sankyo (Japan) |
Cancer - Oncology |